Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.

Namiki K, Matsunaga H, Yoshioka K, Tanaka K, Murata K, Ishida J, Sakairi A, Kim J, Tokuhara N, Shibakawa N, Shimizu M, Wada Y, Tokunaga Y, Shigetomi M, Hagihara M, Kimura S, Sudo T, Fukamizu A, Kasuya Y.

J Biol Chem. 2012 Jul 13;287(29):24228-38. doi: 10.1074/jbc.M111.338541. Epub 2012 May 25.

2.

Pharmacodynamic and pharmacokinetic evaluation of CS-526 in cynomolgus monkeys.

Ito K, Kinoshita K, Yamamura N, Tomizawa A, Inaba F, Morikawa-Inomata Y, Tabata K, Shibakawa N.

Biol Pharm Bull. 2009 Dec;32(12):2010-7.

3.

The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats.

Ito K, Kinoshita K, Tomizawa A, Morikawa-Inomata Y, Inaba F, Fujita Y, Tabata K, Shibakawa N.

J Pharmacol Exp Ther. 2008 Jul;326(1):163-70. doi: 10.1124/jpet.108.137299. Epub 2008 Apr 14.

PMID:
18411413
4.

Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).

Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inomata Y, Makino M, Tabata K, Shibakawa N.

J Pharmacol Exp Ther. 2007 Oct;323(1):308-17. Epub 2007 Jul 13.

PMID:
17630360

Supplemental Content

Loading ...
Support Center